6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience while we make the transition.

Sign in
Back
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group
Journal article   Peer reviewed

Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group

Melanie Birger Morillon, Robin Christensen, Jasvinder A. Singh, Nicola Dalbeth, Kenneth Saag, William J. Taylor, Tuhina Neogi, Martin A. Kennedy, Birthe M. Pedersen, Geraldine M. McCarthy, …
Seminars in arthritis and rheumatism, Vol.51(6), pp.1378-1385
01/12/2021
DOI: https://doi.org/10.1016/j.semarthrit.2021.11.004
Handle:
https://hdl.handle.net/10523/17103

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Serum urate (SU) is the most common primary efficacy outcome in trials of urate-lowering therapies for gout. Despite this, it is not formally considered a validated surrogate outcome. In this paper we will outline the definitions of biomarkers and surrogate outcome measures, respectively as well as the available frameworks and challenges in the assessment of the validity of serum urate as a surrogate in gout (i.e. a reasonable replacement for gout symptoms). (C) 2021 Elsevier Inc. All rights reserved.

Metrics

9 Record Views
5 Times Cited - Web of Science

Details

Logo image